drugset
Drugs / Hepa-B
last change Aug 2024 re-read 2 minutes ago

Hepa-B

Vaccine

Developed for
hepatitis B virus infection
Investigated by
International Centre for Diarrhoeal Disease Research, Bangladesh

Trials 1 · a red edge is where a trial was stopped

today NCT03627507 · Ph 2/3
20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT03627507 Jul 2018 → May 2019 hepatitis B virus infection International Centre for Diarrhoeal Disease Research, Bangladesh Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT02759991 Comparator Oct 2017 → Sep 2019 hepatitis E virus infection Norwegian Institute of Public Health Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Hepa- B “Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine.” NCT03627507 ↗
2

NCT03627507 ↗

NCT02759991 ↗
Modality Vaccine “a control vaccine (Hepa-B, a hepatitis B vaccine)” PMID 39030060 ↗ Aug 2024
Route Intramuscular “Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.” NCT02759991 ↗